FindTrial
Sign In

Study on the curative evaluation of the Gufei Tang in the treatment of combined allergic rhinitis and asthma syndrome

Study on the curative evaluation of the Gufei Tang in the treatment of combined allergic rhinitis and asthma syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17010765
Enrollment
Unknown
Registered
2017-03-03
Start date
2017-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Combined allergic rhinitis and asthma syndrome

Interventions

Treatment group:Granule of Gufei Tang plus Montelukast Sodium Tablets
Control group:Placebo granule of Gufei Tang plus Montelukast Sodium Tablets

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of asthma and allergic and rhinitis; (2) Asthma at chronic duration or remission,and at least 1 times of acute attack of asthma within the past 6 months,persistent allergic rhinitis; (3) Aged 18 to 75 years, both men and women; (4) The chest X-ray examination showed no abnormalities; (5) Positive bronchodilation test or positive bronchial provocation tests; (6) The skin prick test positive and / or serum specific IgE test positive; (7) Patients have informed consent.

Exclusion criteria

Exclusion criteria: (1) Suffering from sinusitis or other serious nasal diseases; (2) Patients with COPD, bronchial dilation, interstitial lung disease, active tuberculosis and so on; (3) Patients with serious primary heart, liver, kidney and blood system diseases; (4) Psychiatric patients; (5) TCM syndrome differentiation with Excess heat syndrome or yin deficiency syndrome; (6) Patients with immunotherapy for more than 3 years; (7) The patient who is attending or preparing attending for another clinical trial; (8) Allergic to the treatment drugs; (9) Pregnancy, breast-feeding or women intending to become pregnant during the course of the study.

Design outcomes

Primary

MeasureTime frame
Frequency of asthma attacks;—

Secondary

MeasureTime frame
The ACT scores;The total dosage of corticosteroid;Lung function;Mini asthma quality of life questionnaire;Symptomatic days due to rhinitis;Rhinitis symptom scores;Rhinoeonjunetivitis quality of Life questionnair;Serum specific IgE;—

Countries

China

Contacts

Public ContactYinji Xu

Guangdong Provincial Hospital of Chinese Medicine

xuyinji@163.com+86 13826173153

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026